For more information or confidential assistance
800-306-3180
se habla español

First Steps Commence in Invokana Litigation

In mid-January, the first steps in the Invokana multidistrict litigation (MDL) began. U.S. District Judge Brian Martinotti, who is presiding over the MDL in the District of New Jersey, announced 1) the pending appointment of a special mediator to deal with discovery issues and settlement possibilities and 2) a “science... Read more »

Report Highlights Risks of Newer Diabetes Drugs

Metabolic acidosis is a risk associated with Invokana that was recently highlighted in a report by the Institute for Safe Medical Practices (ISMP). Invokana is one of the drugs recently touted for its ability to manage type 2 diabetes, but potential side effects have raised concerns and led to a... Read more »

Invokana Lawsuit Filed in Alabama District Court

The drug Invokana belongs to a class of Type II diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, and is referred to generically as canagliflozin. This class of drugs, which also includes well-known brands like Farxiga, Xigdua XR, Jardiance and Glyxambi, was once highly-touted as an innovative alternative for Type II... Read more »

Lawsuit Alleges Kidney Damage after Invokana Use

A plaintiff who recently filed a lawsuit against Invokana manufacturers Janssen Pharmaceuticals and Johnson & Johnson claims use of the drug to treat type 1 diabetes led to serious kidney damage. The lawsuit further accuses the companies of failing to warn consumers and the medical community about the risk associated with... Read more »

Plaintiff Blames Invokana for Severe Kidney Damage

Plaintiff Gene Schurman, a resident of Illinois, claims he suffered severe kidney damage after taking the diabetes drug Invokana under the direction of his doctor. He is now suing Janssen Pharmaceuticals, Johnson & Johnson and Mitsubishi Tanabe Pharma Corporation on claims of failure to warn, product liability, design defect, fraud,... Read more »

Invokana Targeted in Canadian Class Action Lawsuit

Already the subject of increasing controversy in the United States, next generation diabetes drug Invokana is now the target of a newly-filed class action lawsuit in Canada. Filed at the Ontario Superior Court of Justice, the lawsuit alleges that Jannsen’s treatment for Type 2 diabetes poses a serious risk of kidney... Read more »